Company News: ISA Pharmaceuticals’ CSO Prof. Cornelis Melief to Present at CRI-CIMT-EATI-AACR Meeting in New York City
– Prof. Melief co-chairs Plenary Session 1: Antigens and Vaccines
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., and Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO, will jointly chair “Plenary Session 1: Antigens and Vaccines” on September 25, 2016, 8:50 am – 12:00 pm EST at the upcoming CRI-CIMT-EATI-AACR Meeting in New York City.
During the session, Melief will give a presentation titled “Selection of cancer antigens and conditions for success of immunotherapy of cancer involving vaccination”, outlining recent progress in the field.
Company News: Curetis Acquires Patents and Rights to Genetic Antibiotic Resistance and Susceptibility (GEAR) Database and Know-How from Siemens